Tyvaso DPI (treprostinil) Inhalation Powder
Pulmonary Arterial Hypertension (PAH) & PH associated with ILD
ApprovedCommercial (Licensed)
Key Facts
Indication
Pulmonary Arterial Hypertension (PAH) & PH associated with ILD
Phase
Approved
Status
Commercial (Licensed)
Company
About MannKind Corp
MannKind Corporation is a public biopharmaceutical company pioneering inhaled therapeutic delivery systems, primarily for diabetes and pulmonary diseases. Its flagship product, Afrezza, is an FDA-approved rapid-acting inhaled insulin that offers a needle-free alternative for prandial insulin. The company leverages its proprietary Technosphere® platform to develop novel inhaled formulations, with a pipeline targeting endocrine disorders and orphan lung conditions like pulmonary arterial hypertension and pulmonary fibrosis. MannKind's strategy combines commercial execution of Afrezza with pipeline advancement through internal R&D and strategic partnerships.
View full company profile